权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Diagnostic biomarkers of gut microbiome-associated phenotypes predictive of healthy ageing

肠道微生物组相关表型的诊断生物标志物可预测健康衰老

基本信息

批准号：
77886
负责人：
金额：
$ 57.94万
依托单位：
TOPMD PRECISION MEDICINE LTD
依托单位国家：
英国
项目类别：
CR&D Bilateral
财政年份：
2021
资助国家：
英国
起止时间：
2021 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=77886
关键词：
Diagnostic biomarkers gut microbiome associated

项目摘要

Different bacterial populations of gut are associated with longevity and healthy ageing and specific bacteria have been identified which cause immune responses. This project will define combined microbiome and human gene expression biomarker signatures diagnostic of healthy ageing gut phenotypes and associated inflammatory bowel disease (IBD) and/or neurodegenerative disease.We will apply cutting edge measurement of microbiomes and gene expression profiles of gut samples from people aged 50 - 80 with and without inflammatory bowel disease (IBD) and/or neurodegenerative disease. Gene expression biomarkers will be identified using TopMD AI-enhanced technology, developed at the University of Southampton. By applying mathematical topology, TopMD innovatively uses known biological pathways as coordinates for measuring the 'shape' of global gene expression, accurately representing the molecular phenotype as a robust 'pathway biomarker'. In this project, we are working with partner The BioArte Ltd to combined predictive power of microbiome and gene expression signatures. The BioArte Ltd is developing personalised remedies for diseases by identifying molecules obtained from human and animal microbiota. They have led the discovery of immune-regulating bacteria and microbiome signatures predictive of longevity.The combined microbiome- host gene expression biomarker signatures of healthy ageing will be developed into a first of its kind diagnostic point of care test for gut microbiome-associated IBD and neurodegenerative disease in people aged 50-80\.

肠道中不同的细菌种群与长寿和健康老龄化有关，并且已经确定了引起免疫反应的特定细菌。该项目将定义微生物组和人类基因表达生物标志物特征诊断健康衰老肠道表型和相关炎症性肠病（IBD）和/或神经退行性疾病。我们将对50 - 80岁患有或不患有炎症性肠病（IBD）和/或神经退行性疾病的人的肠道样本进行微生物组和基因表达谱的尖端测量。基因表达生物标志物将使用由南安普顿大学开发的TopMD人工智能增强技术进行鉴定。通过应用数学拓扑，TopMD创新地使用已知的生物途径作为坐标来测量全局基因表达的“形状”，准确地代表分子表型作为一个强大的“途径生物标志物”。在这个项目中，我们正在与合作伙伴The BioArte Ltd合作，将微生物组和基因表达特征的预测能力结合起来。BioArte有限公司正在通过识别从人类和动物微生物群中获得的分子来开发个性化的疾病疗法。他们率先发现了免疫调节细菌和微生物组特征，这些特征可以预测长寿。健康衰老的微生物组-宿主基因表达生物标志物联合标记将发展成为50-80岁人群中肠道微生物组相关IBD和神经退行性疾病的首个诊断护理点测试。